Veterinary Vaccines Market to Surpass US$ 9.4 Billion by 2024

The Global Veterinary Vaccines Market was valued at US$ 5,688.7 million in 2015 and is projected to expand at a CAGR of 5.9% during the forecast period (2016–2024), as highlighted in a new report published by Coherent Market Insights. Rise in incidence of food-borne zoonotic diseases along with increase in population of livestock is expected to favor growth of the veterinary vaccines market. According to European food safety authority (EFSA), In the European Union (EU), over 320,000 fatalities are reported each year due to food-borne zoonotic diseases.

Get PDF Research Brochure for more Professional and Technical Insights: https://www.coherentmarketinsights.com/insight/request-sample/125

Zoonoses are infections that directly infect humans or are indirectly transmitted to humans through animals by transmission of micro-organisms such as such as bacteria and their toxins, viruses and parasites. This can be caused due to consumption of contaminated food in contact with infected animals or contaminated meat products. Severity of such diseases varies from mild symptoms to life-threatening conditions. Most such micro-organisms are found in the intestines of healthy food-producing animals. The above concern is one of the major factors projected to propel growth of the market for veterinary vaccines over the forecast period. Furthermore, livestock animals serve as a major source of primary and secondary food products. Rise in population of livestock animals is expected to fuel demand for veterinary vaccines in the near future. Veterinary vaccines promotes better growth of animals. According to WHO, in 2015, children under five years of age accounted for one third of all deaths due to foodborne diseases.

Breakout of zoonotic diseases are dependent on various factors such as environmental changes, demographics related to human and animals, pathogen changes and farming practice modifications. According to Maine Center for Disease Control & Prevention, in 2013, around 75% diseases of animal origin affecting humans were infectious diseases. As animals are the closest companions to humans and also serve as sources of various products such as meat and milk, care should be given according to the severity of the disease from which they can be affected.  The specificity of the vaccines is the most important factor that is responsible for the growth in demand for the veterinary vaccines that can be used as prophylaxis. According to clinical microbiology paper published in 2007, veterinary vaccines comprise around 25%of the animal health products globally. Growth for veterinary vaccines industry has grown consistently supported by various factors such as new technological advancements and introduction of novel vaccine development methods for cost effective products, which further favors the rise in availability and adoption rate for the veterinary vaccines globally. Also, drug resistance to existing pathogens and new diseases is also prompting focus on new drug discoveries.

According to (American Veterinary Medical Association) JAVMA News in 2017, there have been various acquisitions and mergers in veterinary vaccines market in the recent past. However, 85 to 95% of veterinary hospitals in the U.S. are owned independently. Mars Incorporated—a company involved in manufacturing of Petcare, Chocolate, Wrigley, Food and Drinks—is to acquire VCA Inc. – a pet health care services provider in the U.S. and Canada that delivers through nearly around 800 small veterinary hospitals – in total value of around US$ 9.1 billion . Furthermore, in recent years a trend of consolidation has been observed in the industry, as companies are experiencing focusing on leveraging potential through economies of improved business practices. Furthermore, there are various other factors responsible for significant growth in the veterinary vaccines market such as rise in swine population globally and increasing the reach for swine influenza virus globally is projected to favor the market for veterinary vaccines market over the forecast period.

To know the latest trends and insights prevalent in the veterinary vaccines market, click the link below : https://www.coherentmarketinsights.com/market-insight/veterinary-vaccines-market-125

Key takeaways of the market:

• The global veterinary vaccines market is expected to expand at a CAGR of 5.9% during the forecast period (2016–2024). Rise in pet vaccination awareness among the population globally is expected to favor the market for veterinary vaccines market over the forecast period.
• The live attenuated vaccines segment in the global veterinary vaccines market was estimated to be the largest in 2015 and is expected to dominate the market throughout the forecast period in terms of value. Rise in demand for white meat in North America and Europe is expected to fuel the market to high growth over the forecast period
• In terms of animal type, the livestock type sub-segment is expected to expand at a significant CAGR of 5.6% during the forecast period owing to rise in population of livestock animal and the human dependency on the cattle for primary as well as secondary products
• The global veterinary vaccines market is characterized by strategic research and development and advancements in the technology of vaccines production. Also, the rise in adoption for poultry business globally is expected to favor the market for veterinary vaccines market.
• Some of the major players are Zoetis Inc. Merck Animal Health, Merial Inc., Boehringer Ingelheim, Bayer Animal Health, Elanco Animal Health, Ceva Animal Health, Heska Corporation, Virbac Inc., and Indian Immunological Ltd.

About CMI

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Companion Diagnostics Market to Surpass US$ 5.0 Billion by 2024 : Coherent Market Insights

The Global Companion Diagnostics (CDx) Market was valued at US$ 1,614.5 million in 2015 and is projected to expand at a CAGR of 12.0% during the forecast period (2016–2024), as highlighted in a new report published by Coherent Market Insights. Development of multiple biomarkers and targeted drug therapy is boosting research and development collaboration among the industry players. This is expected to improve the time to market for companion diagnostic test products.

Get Free PDF Research Brochure for more Professional and Technical Insights: https://www.coherentmarketinsights.com/insight/request-sample/109

The U.S. FDA lays emphasis on regulatory clearance of companion diagnostics, in its recent draft guidance in 2016, before approving any oncology product that requires and in-vitro diagnostic (IVD) companion diagnostic device for tis safe and effective use. Therefore, drug developers and diagnostic test manufacturers need to work in close collaborations in order to avoid any regulatory bottlenecks. AstraZeneca plc struck a deal with Abbott Laboratories, Inc. in 2015 to develop a companion diagnostic test for tralokinumab, used for treating severe asthma. If successful, this would be the first companion diagnostic test developed for asthma. Moreover, AstraZeneca expects half of its drug launches to include companion diagnostic by 2020. This is a major factor implying the importance of companion diagnostics in treating chronic diseases.

Simultaneous development of a companion diagnostic test and the drug candidate has its own set of pros and cons that act as a trade-off for pharmaceutical companies. Developing companion diagnostic risks holding up of effective drug therapies, and making major investments on companion diagnostics early is a perceived risk, as many drug candidates fail to make it to the market. However, personalized medicine is the emerging therapeutic approach for cancer and other chronic therapies. Thus, developing a companion diagnostic for faster FDA approval makes it imperative for researchers to invest in the development of CDx tests.

Agilent technologies, Inc. announced the extended use of its CE approved Dako PD-L1 IHC 22C3 pharmDx in January 2017, in determining PD-L1 expression status in patients with metastatic non-small cell lung cancer (NSCLC). This device helps determine the expression level of PD-L1 in both untreated and previously treated metastatic NSCLC patients with KEYTRUDA (pembrolizumab), a first-line treatment drug for metastatic NSCLC. With this approval, patients with metastatic NSCLC and in the second-line or later treatment settings can also be identified for treatment with KEYTRUDA.

Invivoscribe Technologies Inc., has companion diagnostics development deal with Novartis AG and Astellas Pharma Inc. Invivoscribe Technologies Inc. has developed a companion diagnostic test for FLT3, a biomarker for the stratification and prognosis of acute myeloid leukemia (AML). This CDx is under the U.S. FDA review for its use with PKC412 (midostaurin) an investigational drug for adults with newly-diagnosed AML and who are FLT3 mutation-positive. If granted approval the LeukoStrat CDx FLT3 Mutation Assay would be the first CDx for AML.

To know the latest trends and insights prevalent in the companion diagnostic market, click the link below: https://www.coherentmarketinsights.com/market-insight/companion-diagnostics-market-109

Approval of the drug and CDx test at the same time is difficult. However, the endeavor to develop effective targeted therapies at low cost and faster time to market would encourage more drug developers to conduct clinical trials with diagnostics as part of the inclusion/exclusion criteria.

Key takeaways of the market:

• The global companion diagnostic market is expected to expand at a CAGR of 12% during the forecast period (2016–2024). Improved clinical outcomes, reduced total research cost and faster time to market are some of the major factors driving collaborations and CDx development globally
• The breast cancer application in the global CDx market was estimated to be the largest in 2015 and is expected to dominate the market throughout the forecast period in terms of value. This is owing to high number of approved brands with CDx tests, driving adoption of these products in treatment of breast cancer.
• In terms of technology, the gene sequencing method segment is expected to expand at a CAGR of 12.6% during the forecast period. Growth of the segment is mainly attributed to increasing focus on identification of genetic mutations that can help in precise identification of the treatment approach for cancer therapies.
• The global companion diagnostics market is characterized by strategic research and development collaborations among the drug and diagnostic test developers. According to the Wildwood Ventures Ltd., the number of global deal in CDx market has increased from 13 in 2007 to 66 in 2013.

Some of the major players are  Abbott Laboratories, Inc., Agilent Technologies, Inc., Danaher Corporation, GE Healthcare, Qiagen N.V., Roche Diagnostics, Biomérieux, Myriad Genetics, Inc., bioMérieux SA, and Siemens Healthcare

About CMI

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Cell Culture Market to Surpass US$ 22.5 Billion by 2024 : Coherent Market Insights

The Global Cell Culture Market was valued at US$ 12,251.3 million in 2015 and is projected to expand at a CAGR of 7.1% during the forecast period (2016–2024), as highlighted in a new report published by Coherent Market Insights. The last century has witnessed a steep rise in number of deadly viruses that cause various diseases. Rise in number of virus infections is expected to propel the cell culture market in the near future. According to W.H.O, in 2015, prevalence of human immunodeficiency virus (HIV) infection in the U.S. is estimated to be 0.32%, which inadvertently fuels growth of the cell culture market.

Get Free PDF Research Brochure for more Professional and Technical Insights: https://www.coherentmarketinsights.com/insight/request-sample/116

Cell culture is an important tool used in the field of molecular biology that offers excellent model systems for studying and analyzing normal physiology and biochemistry of cells. Furthermore, cell culture technique is used in drug screening and development and manufacturing of various biological compounds such as vaccines and therapeutic proteins. Rise in demand for animal and human vaccines is projected to support the cell culture market over the forecast period. High-income countries are characterized by high demand for vaccines in terms of value as compared to low-income countries, as the healthcare standards and awareness about the vaccinations is more in the former. According to WHO, in 2015, high-income countries contributed around 80% of global vaccine sales in terms of value, while accounting for under 20% sales volume. Conversely, around 20% of the global vaccines sales is from the low and middle-income countries contributing to the 80% of the volume of the total vaccines sold. Certain non-profit organizations such as UNICEF and PAHO have high power for low-income countries and middle-income countries. According to WHO, in 2011, the estimated purchase by such groups was around US$ 1.4 billion, which accounted for 7% of the total sales globally.

Product from cell culture are to be utilized as a biomarker for serious conditions such as cancer and also for clinical and diagnostic purpose in various other disease. Centrifugation technique is used for isolation of exosome, which is present in almost every fluid in humans. Companies are focusing on development of new methods for betterment of future healthcare. The implication of exosomes may be in various disorders such as cardiovascular disorder, Alzheimer’s, Parkinson’s and HIV. According to the latest updates in 2017 by International Labmate Limited, the Beckman Coulter’s life sciences division is involved in exosomes isolation process, which concluded that exosomes work under cell-to-cell communication process that is critical for homeostasis. They are further being studied and analyzed for their therapeutic efficiencies under nano delivery device to affected cells. Although the cell culture field consists of various products, their properties can be utilized to clinically treat and diagnose various abnormalities in humans and animals. Companies are inclined towards providing specific products to the customers. For instance, Becton Dickinson (BD) offers customized products and services for characterization of cells and defined environment for cell culture to the customers involved in drug discovery, and cell biology. BD’s custom products and services offers with dependable, reproducible tools. Such tools are able to reduce risks related to technology and finances, which in turn is expected to improve the research quality and operational benefits.

Browse the full Cell Culture Market report at: https://www.coherentmarketinsights.com/market-insight/cell-culture-market-116

Key takeaways of the market:

• The global cell culture market is expected to expand at a CAGR of 7.1% during the forecast period (2016–2024). The increase in number of cancer patients globally is expected to favor the market for cell culture in the near future. According to, Surveillance Research Program, in NCI's Division of Cancer Control and Population Sciences, based on data available between 2009 and 2013, number of new cases of cancer of any site was 448.7 per 100,000 per year.
• The instrument product type segment in the global cell culture market was estimated to be the largest in 2015 and is expected to dominate the market throughout the forecast period in terms of value. Rise in number adoption for vaccination worldwide in lower and middle-income countries in terms of volume. According to W.H.O, in 2016, around 19.4 million infants are still deprived of necessary vaccinations.
• The cancer research application segment is expected to expand at a CAGR of 8.0% during the forecast period. This is expected to support the market on the backdrop of increase in global biopharmaceutical market due to the cost-effectiveness and high efficacy of the products.
• The global cell culture market is characterized by rise in focus on biopharmaceutical and other biological products. For instance, according to McKinsey & Company, in 2015, biopharmaceuticals contributes to around 20%, which is around US$163 billion of the total pharma market. This is expected to increase and to support the cell culture market.
• Some of the major players are Becton, Dickinson and Company, EMD Millipore, Sartorius AG, Merck KGAA, Biospherix, Sigma-Aldrich Corporation, Biovest International Inc. Cell Culture Company, LLC.

About CMI

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Negative Pressure Wound Therapy Devices: Clearing Dark Clouds of Pain

Extending pain relief to people in distress is the noblest of all ‘karmas’ and this nobility has bestowed an exponentially growing status to the global negative pressure wound therapy (NPWT)  devices market over the last three decades. Negative wound therapy, also called vacuum-assisted wound closure (VAC), refers to systems that aid rapid wound healing by applying sub-atmospheric pressure to the affected area and is especially beneficial in treatment of acute and chronic wounds. NPWT devices find wide application for treatment of wounds among the geriatric population and diabetic patients, as this demographic group is highly susceptible to wounds, given their lower bodily function and high morbidity.

Get Free PDF Research Brochure for more Professional and Technical Insights: https://www.coherentmarketinsights.com/insight/request-sample/103

As per statistics released by the Administration of Aging, part of the U.S. Department of Health and Human Services, the geriatric population accounted for 14.5% of the population in the U.S. in 2014, which is further expected to reach 21.7% by 2040. The World Health Organization revealed that number of diabetic patients worldwide increased from 108 million in 1980 to 422 million in 2014. NPWT devices greatly help curtail complications resulting from injuries in diabetic patients, which if left untreated can result in leg amputation. The elderly population has sensitive skin, which can be easily damaged, and tissue heals slowing due to slower or non-reproduction of cells; NPWT ensures speedy recovery by drawing out fluid from the wound and increasing blood flow to the area. Thus, rapidly increasing prevalence of diabetes and growing aging population in advertently creates a highly conducive market for NPWT devices market. Chronic and acute traumatic wounds like second-degree burns, diabetic foot infections, open abdomen and also bed-sores and ulcers are specific areas in which the NPWT devices heal by applying reduced local pressure using occlusive dressing connected to a vacuum pump. Furthermore, increasing hospital visits due to rising prevalence of injuries fuels demand for effective wound treatment methods such as negative pressure wound therapy. As per statistics released by the Centers for Disease Control and Prevention (CDC), an average of 126.3 episodes of injury are reported of 1,000 population in the U.S. each year.

On the basis of product types, NPWT devices are classified as standalone, portable, and disposable devices, each with a very specific application. Standalone NPWT devices are mains-operated, used in hospitals for acute traumatic bed-ridden patients, and are exorbitantly priced. These devices have a stronghold in the market, with major growth expected in the near future. This is attributed to decreasing prices and rapid surge in accident victims worldwide. The 2013 World Health Organization Status Report on Road Safety estimated that approximately 1.24 million deaths occur annually due to road traffic crashes. Portable and disposable devices are beneficial for ambulatory patients, with a stipulated timeline of use making them a preferred choice in home-setting treatments. Portable and disposable negative pressure wound therapy devices have drastically reduced hospital in-patient stay, related expenses, and lower incidence of related hospital-induced diseases. Various features such as lightweight, ease of use, cost-effectiveness of these disposable devices make them highly sought after by out-patient population.

Negative pressure wound therapy devices getting smarter

Smart-enabled NPWT devices have opened a plethora of possibilities in healthcare, significantly elderly patients. The conventional NPWT setup once implemented will transform into a mobile device with a modem, automated through cloud-services enabling continuous real-time monitoring and periodic notifications to caregivers. It would help track usage, provide technical support and maintain documentation for reimbursement thus reducing the enormity of the treatment in terms of time, cost and enhancing effective, cohesive care. Though in the nascent stage, SWAN-iCARE is a project currently in the research phase. The product is an automated wearable negative pressure device that constantly monitors and administers personalized management of chronic wounds, mainly diabetic foot ulcers and venous leg ulcers`.

APAC economic boom catapulting NPWT devices market growth

Diabetes is among the leading causes of death in the U.S. Around 1.4 million new diabetes cases are diagnosed each year as per statistics released by the American Diabetes Association. Regulatory reforms initiated by the Centers for Medicare and Medicaid Services, provide for full reimbursement coverage for conventional and disposable NPWT devices under Medicare Hospital Outpatient Prospective Payment System (OPPS), effective January 1, 2017. This positions the country to continue to be the most lucrative market for negative pressure wound therapy devices over the following decade, followed by Europe, due to high healthcare spending in the latter. However, the swelling expenditure capacity and increasing healthcare awareness in the Asia Pacific region, coupled with high economies of scale that can be leveraged by manufacturers, is expected to lead to rapid growth of the market for NWPT device in the region..

Big wheels of the Global Negative Pressure Wound Therapy Market

Smith and Nephew, Acelity, Conva Tec Inc, Medela, Molnlycke Health Care, Paul Hartman AG, Coloplast Corp are among the leading players in the NPWT devices market. Kinetic Concepts, now acquired by Acelity, was among the pioneers in the NPWT devices market in the U.S. In 2012, Smith and Nephew spearheaded innovation introducing disposable NPWT devices, which are cost-effective; thus, steering towards capitalization on lucrative growth opportunities in cost sensitive markets of Asia Pacific, Latin America, and the Middle-East. Conventional standalone NPWT devices are bulky and rather cumbersome to use and require a power source. Thus, companies are focused towards development of alternatively powered devices that are more portable and easy to use. Smart Negative Pressure (SNaP) Wound Care System is one such non-electrically powered ultraportable NPWT device that is expected to be commercialized in the near future.

To know more about the latest market trends and insights, read the report titled ‘‘GLOBAL NEGATIVE PRESSURE WOUND THERAPY (NPWT) DEVICES MARKET, published by Coherent Market Insights. Click on the link below to access the report : https://www.coherentmarketinsights.com/market-insight/negative-pressure-wound-therapy-devices-market-103

Interestingly, yet sadly, increasing global prevalence of diabetes has fuelled growth of the negative pressure wound therapy devices market. Uptake of these devices is currently hampered by high costs and lack of awareness about them. However, as a result of its various properties such as faster healing, lesser number of dressings required, and increasing awareness initiatives by companies the advent of portable and disposable devices have balanced out the cost factor. Countering low product-availability and lack of skilled-professionals would further enhance the lucrative growth of the NPWT market.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Global CAR T Cell Therapy Market, By Targeted Antigen, Therapeutic Application, and Geography - Trends, Analysis and Forecast till 2028

CAR T cell therapy has been a major buzzword for a while, owing to its effectiveness in treating blood cancer. These are the genetically engineered receptors that targets surface molecules in patient’s immune system. T cells are collected from patients and are genetically engineered in the laboratory in order to multiply them by millions. These T cells are further injected in patients to offer immunity and guard against recurrence of tumorous cells.

Get Free PDF Research Brochure for more Professional and Technical Insights: https://www.coherentmarketinsights.com/insight/request-sample/102

Market Dynamics

CAR T cell therapy is expected to be a game changer post its commercialization creating revenue opportunities for players in the CAR T cell therapy market. Moreover, it is expected to help with effective diagnosis of acute lymphoblastic leukemia (ALL) in B cells of children. Introduction of the drug is expected to be especially beneficial for leukemia patients. According to the U.S. National Cancer Institute, over 340,000 people in the U.S., suffered from leukemia in 2015, with an estimated 1.5% of the population in the country expected to be detect with leukemia once in their lifetime. Growing prevalence rate and increasing demand for effective treatment modalities is expected to pave way for market growth over the forecast period.

The CAR T cell therapy market is expected to be highly consolidated over the next few years, with the three major players accounting for around half of the overall market revenue share. This novel therapeutic application is expected to create lucrative profit margins for industry players across the value chain, ranging from manufacturers to distributors and end-use hospitals.

Market Taxonomy

This report segments the CAR T cell therapy market on the basis of antigen type, and therapeutic applications. On the basis of antigen, CAR T cell therapy market is segmented as CD 19, CD 20, GD2, CD22, CD30, CD33, HER1, HER2, Meso, EGFRvlll, and others.

Browse Global Strategic Business Report : https://www.coherentmarketinsights.com/market-insight/car-t-cell-therapy-market-102

On the basis of therapeutic applications, CAR T cell therapy market is segmented into acute lymphocytic leukemia, chronic lymphocytic leukemia, non-hodgkin leukemia, multiple myeloma, pancreatic cancer, neuroblasta, breast cancer, acute myeloid leukemia, hepatocellular carcinoma, colorectal cancer, and other therapeutic applications.

Key features of the study:

• This report provides in-depth analysis of the CAR T cell therapy market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR) (%) for the forecast period (2017 – 2028)
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides valuable insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
• The report takes into account critical limiting factors such as accuracy issues and need for calibrating the device several times a day while analyzing the market value and growth (%) during the forecast period
• It includes insights on population dynamics, number of dental clinic centers, and demand for CAR T Cell Therapy across the globe.
• It profiles leading players in the global CAR T Cell Therapy market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies and future plans
• Key companies covered as a part of this study include Juno Therapeutics, Kite Pharma Inc., Novartis International AG, Bellicum Pharmaceuticals Inc., Celgene Corporation, and Cellectis.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions with respect to their future product launch, technology upgrade, market expansion, and marketing tactics
• The global CAR T Cell Therapy market report caters to various stakeholders in this industry, including investors, raw material manufacturer, contract manufacturer, device manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would greatly benefit in decision making through the various strategy matrices used in analyzing the CAR T Cell Therapy market.

ABOUT US

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Bone Cancer Treatment Market - Industry Insights, Trends, and Opportunity Analysis, 2016-2024

Bone Cancer Treatment Market Overview

Cancer is one of the most prevalent fatal chronic disorders with a high mortality rate due to its extremely invasive nature and prolonged duration of disease. Bone cancer is a type of cancer in which the bone tissues grows in an uncontrollable manner. This growth may be benign or malignant. In most cases bone cancer results from other cancers such as lung cancer, kidney cancer, prostate cancer, and breast cancer, which is also called secondary or metastatic bone cancer. The major and primary symptom of bone cancer is severe bone pain, which usually intensifies with time. In addition to pain, symptoms such as weight loss, fever, fatigue, muscle pain, bone crack, osteoporosis and osteopenia are also identified. Diagnosis of bone cancer includes understanding patient’s history and reasons causing pain. Besides, bone cancer can be diagnosed using imaging techniques such as computerized tomography (CT), bone scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scanning, and biopsy tests.

Get Free PDF Research Brochure for more Professional and Technical Insights: https://www.coherentmarketinsights.com/insight/request-sample/93

Bone cancer treatment market can be classified on basis of type and treatment available for bone cancer

The bone cancer treatment market is analyzed on the basis of type of bone cancer into primary bone cancer and secondary bone cancer. Primary bone cancer originates from fast and uncontrollable growth of the bone and other related tissues. Types of primary bone cancer include osteosarcoma, chondrosarcoma, Ewing’s sarcoma, spindle cell sarcoma, and chordoma. Secondary bone cancer, also called metastatic bone cancer, arises due to spreading of cancer cells from different parts of body. It is also referred as metastatic bone cancer.

On the basis of therapies or treatments available, the global bone cancer treatment market is classified as radiation therapy, chemotherapy, cryosurgery, and surgical treatments. The major surgical practices used to treat bone cancer are limb amputation surgery and limb salvage surgery or limb sparing surgery. In radiation therapy, high energy X-rays or gamma-rays are used to destroy tumors. Chemotherapy is a pharmacological treatment that involves the use of anti-cancer drugs. Major drugs include strontium-89 chloride, bisphosphonates, methotrexate, and doxorubicin, among others. Cryosurgery is sometimes used in lieu of conventional surgery to kill tumors.

Increasing disease incidence creating favorable growth environment for Bone cancer treatment market

Developed markets such as the U.S., U.K., Japan, Canada, Australia, Germany, and Spain have a robust healthcare infrastructure that provides patients with easy access to advanced healthcare facilities, which aids in early diagnosis of bone cancer. According to the American Cancer Society (ACS), approximately 3,300 new cases of bone cancer are expected to be diagnosed in 2016, resulting in around 1,490 deaths in the same year. Moreover, the ACS sates that in adults over 40% of primary bone cancers are chondrosarcomas. This is followed by osteosarcomas (28%), chordomas (10%), Ewing tumors (8%), and malignant fibrous histiocytoma/fibrosarcomas (4%). According to 2016 Cancer.Net estimates, 3,300 people of all ages in the U.S. would be diagnosed with primary bone cancer. New cases of bone cancer being diagnosed would propel growth of the bone cancer treatment market in the U.S. On the other hand, rising incidence rate in Asia Pacific is expected to be a major growth factor for the global bone cancer treatment market, supported by growing awareness among the populace.

Browse Global Strategic Business Report : https://www.coherentmarketinsights.com/ongoing-insight/bone-cancer-treatment-market-93

Global players involved in the bone cancer treatment market

Major players involved in bone cancer treatment market include Amgen Inc., Actavis plc, Novartis International AG, Debiopharm Group, Pfizer, Inc., and Eli Lilly and Company.

Dr. Andre Roodt, a researcher at the University of Free State has developed pain relieving drug for bone cancer patients in December 2016. The drug is a liquid radioactive isotope that can detect cancer in the body. Innovation in treatment options would lead to better therapeutic outcomes.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Clinical Laboratory Services Market, By Test Type, Service Provider, and Geography - Trends, Analysis and Forecast till 2024

Clinical laboratory tests are an integral part of healthcare industry, aiding effective diagnosis of diseases. The tests conducted at diagnostic laboratories enable identification of the epidemiology of disease, the resultant abnormalities, level of progression (stage) of the disease, and imbalances in the physiology. With growing competition, clinical laboratories are providing additional services such as free-home pick-up of the blood and urine sample, sharing medical reports directly with the concerned physician, and regular updates/reminders for health check-up. The clinical test equipment manufacturers such as Quest Diagnostics, Inc. and Abbott Laboratories are constantly working on improving their laboratory products to shorten the duration of test and increase product efficiency. This enables effective management of clinical laboratories.

Get Free PDF Research Brochure for more Professional and Technical Insights: https://www.coherentmarketinsights.com/insight/request-sample/87

Market Dynamics

According to the United Nations 2015 World Population Prospects Report, the number of people aged 60 years and above is expected to grow by 56% to reach 1.4 billion by 2050. Aging increases the risk of infections and chronic disorders such as arthritis, atherosclerosis, cancer, liver diseases, and diabetes. This makes the geriatric population a key target group for diagnostic tests. Increasing health consciousness and awareness among people for regular-health check-ups for identifying signs of any disease have also increased number of visits to laboratories. Also, diagnostic laboratories are launching multiple health packages for routine health check-ups and encouraging the general population to perform routine health check-up at least once a year. Such initiatives from the clinical test service providers is also fueling the demand for clinical laboratory services.

Market Taxonomy

This report segments the global clinical laboratory services market on the basis of test type and service provider. On the basis of test type, the global clinical laboratory services market is classified as clinical chemistry, medical microbiology & cytology, human & tumor genetics, and other esoteric tests. Service providers include clinic-based laboratories, hospital-based clinical laboratories, and standalone clinical laboratories.

Key features of the study:

·         This report provides in-depth analysis of clinical laboratory services in medical sector and provides market size (US$ million) and Cumulative Annual Growth Rate (CAGR) (%) for the forecast period (2016 – 2024), considering 2015 as the base year

Browse the full Clinical Laboratory Services Market report at: https://www.coherentmarketinsights.com/market-insight/clinical-laboratory-services-market-87

·         It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

·         This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players

·         It profiles leading players in the global clinical laboratory services market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans

·         Key companies covered as a part of this study include Abbott Laboratories, Laboratory Corporation of America Holdings (Labcorp), Bio-Reference Laboratories, ARUP Laboratories, Charles River Laboratories, Labco S.A., Genoptix Medical Laboratory, Quest Diagnostics, Inc., Healthscope Ltd., Spectra Laboratories and Sonic Healthcare Limited

·         Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion and marketing tactics

·         The global clinical laboratory services market report caters to various stakeholders in this industry, including investors, clinical laboratory equipment suppliers and distributors, new entrants, and financial analysts

·         Stakeholders would have ease in making decision through the various strategy matrices leveraged in analyzing the clinical laboratory services market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Negative Pressure Wound Therapy Devices Market to Surpass US$ 2.7 Billion by 2024 : Coherent Market Insights

The Global Negative Pressure Wound Therapy Devices Market was valued at US$ 1,626.3 million in 2015 and is projected to expand at a CAGR of 5.5% during the forecast period (2016–2024), as highlighted in a new report published by Coherent Market Insights. Better clinical outcomes and faster patient recovery facilitated by NPWT devices significantly drive their adoption.

NPWT devices are used on wounds that are too large or deep to be secured using staples and stitches. Wound therapy is an absolute necessity post-surgery and thus, has a potential application base that includes millions of people undergoing surgery across the globe each day (312.9 million in 2012, WHO).

Get Free PDF Research Brochure for more Professional and Technical Insights : https://www.coherentmarketinsights.com/insight/request-sample/103

NPWT which works like a vacuum seal, offers faster and safer patient recovery with minimal risk of infection as compared to conventional wound therapy devices such as staples, sutures, and biological dressings. Availability of reimbursement is further fueling demand for NPWT devices, especially in developed economies such as the U.S., Germany, and the Netherlands, to name a few.

Unlike conventional wound treatment systems that need to be replaced every day, NPWT devices need to be replaced just three times a week, significantly reducing patient stress and aiding speedy recovery. Moreover, advancements in technology have led to introduction of canister-less NPWT devices. ConvaTec Group plc, launched its first NPWT device, Avelle, in August 2016. The company launched its product in the U.K., which utilizes AQUACEL technology (prevents periwound maceration) and is a simple, canister-less, disposable system with a 30-day life.

PICO, from Smith & Nephew plc, received the 2016 French Galien Award. PCIO is a single-use NPWT device that significantly reduces total cost and care needed for patients with pressure ulcers, dehisced surgical wounds, diabetic foot ulcers, leg ulcers, and trauma wounds. The Prix Galien award acknowledges advances in pharmaceuticals and medical devices that improves the quality of human life.

In 2016, studies published in the ‘WOUNDS’ journal concluded that use of zinc-coated foam and silver-impregnated dressings along with NPWT in complex wound therapy demonstrated better clinical outcomes and faster recovery in patients as compared to conventional wound treatment methods. This further encourages the use of NPWT as an adjunctive therapy in wound treatment. To add to this, use of non-powered or mechanical MPWT devices allows a silent delivery of therapy with a much lighter weight than electrical NPWT devices.

To know the latest trends and insights prevalent in the negative pressure wound therapy devices market, click the link below : https://www.coherentmarketinsights.com/market-insight/negative-pressure-wound-therapy-devices-market-103

Key takeaways of the market:

• The global negative pressure wound therapy devices market is expected to expand at a CAGR of 5.5% during the forecast period. Better clinical outcomes, reduced total therapy cost and availability of reimbursement are some of the major driving factors for market growth.
• The portable NPWT devices market is expected to gain traction at 5.8% during the forecast period (2016 – 2024). High demand for these devices is mainly attributed to the fact that these provide the flexibility to continue therapy at home.
• Diabetic foot ulcers is projected to be a major revenue contributing application segment, owing to high prevalence of diabetes and lack of proper management of the disease leading to increasing incidence of related foot ulcers
• North America lead the global NPWT devices market with a share of over 50% in 2016. Rapid adoption of new technologies, availability of reimbursement and high patient awareness are factors attributable to its leading market share
• Intense competition is witnessed among the leading players such as Smith & Nephew plc, Devon Medical, Paul Hartmann AG, Talley Group Limited, Coloplast A/S, ConvaTec Inc., Molnlycke Health Care AB, Medela AG, Kinetic Concepts, Inc., and Cardinal Health, Inc.
• Companies are launching devices with advanced technology, offering high convenience and cost benefit to the patients (example PICO by Smith & Nephew plc and Avelle by ConvaTec Group plc)

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Artificial Pancreas Market - Industry Insights, Trends, and Opportunity Analysis, 2016-2024

Artificial pancreas is a disruptive technology that is expected to revolutionize the diabetes market in near future especially for type 1 diabetes treatment. Type 1 diabetes, characterized by inadequate insulin production, requires daily administration of insulin to regulate the amount of glucose in the body. Thus, patients suffering from type 1 diabetes need to be regularly monitor their blood glucose levels and administer insulin accordingly. According to the World Health Organization (WHO), number of diabetes patients worldwide has increased from 108 million in 1980 to 422 million in 2014. According to Juvenile Diabetes Research Foundation (JDRF), there were around 1.5 million type 1 diabetics worldwide in 2015. There are no commercially available treatment option for type 1 diabetes. Therefore, organizations such as JDRF and OpenAPS are focusing only on developing effective and compliant therapies for type 1 diabetes. Artificial pancreas market outlook is optimistic for early entrants.

Get Free PDF Research Brochure for more Professional and Technical Insights : https://www.coherentmarketinsights.com/insight/request-sample/79

Medtronic’s MiniMed 670G – The First of its Kind in Artificial Pancreas Market Outlook

Medtronic entered the artificial pancreas market with introduction of MiniMed. MiniMed 670G—the first of its kind artificial pancreas for treatment of diabetes 1—received FDA approval in September 2016. The device would be made available in 2017. MiniMed 670G combines an automated glucose monitor and an insulin pump. The FDA has granted approval for this device to be used in patients aged 14 years and above. Once additional real-life tests are successfully carried out by the company, the product would be accessible to the target user group, mainly the pediatric population.

MiniMed 670G is a hybrid closed-loop system that automates the cumbersome process of monitoring and adjusting glucose and insulin levels in type 1 diabetes patients. Patients can monitor health through a device like a smartphone. This artificial pancreas would help patients sleep well at night and wake-up with a healthy glucose levels. Moreover, Medtronic’s MiniMed 670G artificial pancreas would improve therapy adherence and allow patients to live life unlike previously where there was a need for regular intervention. Various regional players are expected emerge in the artificial pancreas market in near future in order to capitalize on lucrative growth opportunities.

However, emergence of other disruptive technology could somewhat affect the overall growth of artificial pancreas market revenue. For instance, automated insulin delivery device is a prospective alternative to artificial pancreas. OpenAPS—a do-it-yourself (DIY) automated insulin delivery system—is an open source design that can be used by anyone to connect their CGM and insulin pump to make it an artificial pancreas. The device was developed in 2013 by Ben West, Dana Lewis, and Scott Leibrand.

Browse Global Strategic Business Report : https://www.coherentmarketinsights.com/ongoing-insight/artificial-pancreas-market-79

North America and Europe to dominate the Artificial Pancreas Market Size

According to the Center for Disease Control and Prevention (CDC), there were 29.1 million diabetic patients in the U.S. in 2015, of which 8.1 million are undiagnosed. Type 1 diabetes accounts for around 5% of the total diagnosed diabetes cases in adults in the U.S. Type 1 diabetes is common among Scandinavian population and in Sardinia and Kuwait and less common in Asia and Latin America. Developed regions are expected to dominate the artificial pancreas market size, owing to early adopters of disruptive technology. Success achieved in these markets influences companies to enter into emerging markets, where the regulations, distribution and purchase/treatment patterns vary widely.

Conclusion

Medtronic’s MiniMed 670G artificial pancreas only needs to be calibrated by the patient, while the rest is taken care of by the automated device. Adoption would be a little slow, especially in developing countries, considering the high price of the device. However, given the long-term gains from the device, adoption is expected to increase over time. According to the CDC, the annual healthcare burden due to diabetes to the U.S. government was US$ 176 billion in 2012. Governments and insurance providers are pushing pharmaceutical and medical device companies to reduce medicine and device costs. This is expected to have a significant impact on the pricing of the artificial pancreas. There is high demand for effective treatment of diabetes. As such, addressable market is expected to generate high return on investment (ROI) for artificial pancreas market players.

About Coherent

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. Our global team of over 100 research analysts and freelance consultants provide market intelligence from the very molecular country level and also provide a global perspective of the market. Our team is of the most vital cog in our robust machinery that gives us the ability to deliver independent insight relying on our cognitive defusion training module.This allows for an objective and unbiased assessment of the market. We pride ourselves in my constantly striving to update our extremely in-depth understanding of the market by closely monitoring and analyzing markets, trends, and emerging best practices, across allfathomable industries under the sun. This enables us to equip our valued clientele with key decisive inputs to capitalize on lucrative growth opportunities in the market and to follow firmly position themselves on a high growth path in the future.

Cardiovascular Information System Market-Industry Insights, Trends, and Opportunity Analysis, 2016-2024

Rampant rise in incidence rate of cardiovascular diseases worldwide, is fueling demand for a system that can aid physicians in managing patient’s cardiovascular medical records. This cardiovascular information system is a web-based system that would allow easy report generation and distribution. The cardiovascular information system (CVIS) provides on-time access to cardiovascular electronic medical records (EMR) in images, reports, and waveforms. The prime benefit of cardiovascular information system is that the patient safety and quality of care is improved by providing healthcare experts access to individual’s cardiovascular medical records. Implementation of cardiovascular information system would help hospitals eliminate duplicate entries and reduce errors. From the formulation of operational strategies to the use of multiple functionalities from multiple locations, cardiovascular information system has been immensely useful and efficient.

Get Free PDF Research Brochure for more Professional and Technical Insights : https://www.coherentmarketinsights.com/insight/request-sample/20

Cardiovascular Information System Market Taxonomy

The cardiovascular information system market can be analyzed on the basis of application as follows: 

• Cardiac and peripheral catheterization: This involves the insertion of a catheter into the heart chamber for the diagnosis and treatment of a particular heart condition
• Hemodynamics monitoring: It is based on invasive measurement of cardiac output, pulmonary arterial, and venous pressures
• Electrophysiology: Electrophysiology is characterized by the study of diagnosis and treatment of electrical activities of the heart
• Echocardiography: An echocardiogram is a test used to create images of the heart with the help of sound waves
• Vascular ultrasound: Vascular ultrasound is a painless and non-invasive test to create images of arteries and veins, using a high-frequency sound waves
• Nuclear cardiology: Nuclear cardiology involves the usage of a radioactive tracer into the bloodstream for the identification of coronary heart disease and severity of prior heart attacks

On the basis of system, the cardiovascular information system market has been segmented as follows:

• CVIS
• CPACS

On the basis of software delivery mode:

• Cloud
• On-premise

On the basis of end users:

• Hospitals
• Diagnostic Laboratories
• Private Clinics

Cardiology picture archiving and communication systems (CPACS) are slightly different from the radiology picture archiving and communication systems (PACS), in terms that CPACS support DICOM structure reporting for echocardiography measurements that is lacking in the PACS. The CVIS system on the other hand is data driven and stores patient information in the CVIS database for patient record and data reporting.

Cardiovascular Information System Market Outlook - Growing Integration of Healthcare and IT to boost demand in Developing Nations

On the basis of geography, the global cardiovascular information system market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America and Rest of the World (RoW). Prime factors contributing towards growth of cardiovascular information system market are increasing need to streamline the workflow and strengthen referral relationships, thereby focusing more on patient care. Furthermore, creation of a single point of access to all cardiac images helps physicians to make better treatment decisions at timely intervals. Asia Pacific is expected to emerge as a major market in the near future, mainly due to growing demand of cardiologists to produce a report from the CPACS while viewing the cardiac images, and appropriate integration of reports, images and measurements into a patient’s complete record. Also, increasing need to create an enterprise information management solution and need to reduce healthcare costs would also propel growth of cardiovascular information system market.

Various companies provide cardiovascular information system to hospitals for a better and streamlined flow of procedures. Some of the top companies operating in the cardiovascular information system market are McKesson Corporation, Philips Healthcare, GE Healthcare, Cerner Corporation, Merge Healthcare, Agfa Healthcare, Siemens Healthcare, Agfa Healthcare, Fujifilm Medical Systems, Digisonics, Inc., and Lumedx.

ABOUT US

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. Our global team of over 100 research analysts and freelance consultants provide market intelligence from the very molecular country level and also provide a global perspective of the market. Our team is of the most vital cog in our robust machinery that gives us the ability to deliver independent insight relying on our cognitive defusion training module.This allows for an objective and unbiased assessment of the market. We pride ourselves in my constantly striving to update our extremely in-depth understanding of the market by closely monitoring and analyzing markets, trends, and emerging best practices, across allfathomable industries under the sun. This enables us to equip our valued clientele with key decisive inputs to capitalize on lucrative growth opportunities in the market and to follow firmly position themselves on a high growth path in the future.